Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5. Its lead product candidate, Nomacopan, is a recombinant small protein (16,740 Da) that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (membrane attack complex (MAC)), and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response. The Company’s pipeline includes two late-stage programs for bullous pemphigoid (BP) and thrombotic microangiopathy (TMA), as well as earlier stage research and development programs in eye and lung diseases with unmet need. Its pre-clinical programs include Nomacopan LA, Votucalis and others.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)